NTLA
Intellia Therapeutics Inc

12,798
Loading...
Loading...
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
403

Frequently Asked Questions

What is Market Cap of Intellia Therapeutics Inc?
What is the 52-week high for Intellia Therapeutics Inc?
What is the 52-week low for Intellia Therapeutics Inc?
What is Intellia Therapeutics Inc stock price today?
What was Intellia Therapeutics Inc stock price yesterday?
What is the PE ratio of Intellia Therapeutics Inc?
What is the Price-to-Book ratio of Intellia Therapeutics Inc?
What is the 50-day moving average of Intellia Therapeutics Inc?
How many employess does Intellia Therapeutics Inc has?

Latest NTLA News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.